Senores Pharmaceuticals IPO analysis

Senores Pharmaceuticals IPO (initial public offering) will open for subscription on December 20, 2024, and close on December 24, 2024. Here is a breakdown of the pharmaceutical company's strengths, weaknesses and growth prospects to help investors make an informed decision. Senores Pharmaceuticals IPO in a nutshell Quality : Between FY22 and FY24, the company reported a three-year average ROE and ROCE of around 16.5 and 8.9 per cent, respectively. rowth : Between FY22 and FY24, its revenue and profit after tax grew by 289.1 and 474.5 per cent per annum. Valuation : At the upper end of the price band of Rs 391, the stock has a P/E and a P/B ratio of nearly 55.1 and 2.3 times, respectively. Overview: Senores Pharmaceuticals stands to take advantage of increasing expenditure and growing penetration of pharmaceuticals across the globe. Its presence in regulated and unregulated markets for off-patented generic products works in its favour. However, the lack of entry barriers and stiff competition in the generic drugs space can hurt its growth prospects. About Senores Pharmaceuticals Incorporated in 2017, Senores Pharmaceuticals primarily manufactures off-patent generic products and operates two manufacturing facilities in the US and India (Ahmedabad). It operates in over 45 countries, including the regulated markets of the US and Europe, which contributed to almost 61 per cent of its total revenue in H1 FY25. Along with targeting the competitive generic drugs with a six-month exclusive sales right guarantee, Senores Pharmaceuticals has also partnered in sales agreements with companies like Sun Pharma, Dr Reddys, Alkem Laboratories, etc., to expand its product portfolio in the regulated markets. The company also does contract development for new drugs, which contributed to nearly 14 per cent of its revenue in H1 FY25. Strengths of Senores Pharmaceuticals Long-term partnerships: Senores Pharmaceuticals boasts long-term sales partnerships with large, well-established players like Sun Pharma, Alkem, Jubilant, etc, along with manufacturing for big names in the US. Such partnerships with industry titans can help the company establish a significant presence across markets. Weaknesses of Senores Pharmaceuticals Negative cash flows: Between FY22 and FY24, Senores Pharmaceuticals reported negative cash flow from operations. This was primarily due to higher working capital requirements as the company's operations scaled up significantly post the acquisition of Havix and Ratnatris. Regulatory issues: Senores Pharmaceuticals' US-based facility came under scrutiny from the US FDA in 2022, which cleared recently. Such regulatory actions can significantly impact its financials. Senores Pharmaceuticals IPO details Total IPO size (Rs cr) 582 Offer for sale (Rs cr) 82 Fresh issue (Rs cr) 500 Price band (Rs) 372-391 Subscription dates December 20-24, 2024 Purpose of issue Repayment of debt, investment in subsidiaries and potential acquisitions Post-IPO M-cap (Rs cr) 1,801 Net worth (Rs cr) 792 Promoter holding (%) 45.8 Price/earnings ratio (P/E) 55.1 Price/book ratio (P/B) 2.3 Financial history